Evidence-Based Strategies for Managing Neurogenic Bladder

Maha Alturqi Bulyhed Alruwaili [1], Manar Arif Alruwaili [2], Alshreef, Samiah Yahia A [3], Nasser Mohammed N Aldaham [4], Alruwaili, Itizaz Mofareh H [5], Bader Faris Daham Altimyat [6], Nasser Hajij Alanazi [7], Khalad Abdulrhman M Alshamrane [8], Khattam Awad S Alruwili [9], Amirah Zaben Jodia Aruwaili [10]

[1]Nursing specialist, Maternity and Children Hospital in Aljouf, Sakaka, Aljouf, Saudi Arabia
[2]Nursing specialist, Turaif General Hospital - Turaif, Saudi Arabia.
[3]Nursing specialist, East Jeddah Hospital -Jeddah Health Cluster 1, Saudi Arabia.
[4]Nursing specialist, Prince Muteb bin Abdulaziz Hospital, Sakaka, Al-Jouf, Saudi Arabia.
[5]Nursing specialist, Maternity and Children Hospital in Aljouf, Sakaka, Aljouf, Saudi Arabia
[6]Nursing technician, Maternity And Children Hospital In Rafha, Saudi Arabia.
[7]Nursing technician, North Medical Tower at Arar in Saudi Arabia
[8]Nursing technician, Medical rehabilitation and Care Hospital - Arar, Saudi Arabia.
[9]Nursing technician, Prince Muteb bin Abdulaziz Hospital, Sakaka, Al-Jouf, Saudi Arabia.
[10] Nursing, Prince Muteb bin Abdulaziz Hospital, Sakaka, Al-Jouf, Saudi Arabia.

Abstract:

Neurogenic bladder is a condition resulting from nerve dysfunction, leading to difficulties in bladder control, which can manifest as overactive bladder, underactive bladder, or urinary retention. Evidence-based strategies for managing this condition include a combination of pharmacological and non-pharmacological interventions. Medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogen can be used to manage overactive bladder symptoms. In contrast, for underactive bladder, patients may benefit from using intermittent catheterization or medications like cholinergic agents to stimulate bladder contraction. Additionally, lifestyle modifications, pelvic floor exercises, and bladder training can provide significant improvements in bladder function and quality of life. Another critical component of managing neurogenic bladder is patient education and self-management. Educating patients about their condition, bladder health, and effective strategies, such as timed bathroom visits or fluid management, empowers them to take an active role in their treatment. Furthermore, regular follow-up appointments can help monitor symptoms and adjust treatment plans as needed. Advanced interventions, such as neuromodulation or surgical options like bladder augmentation or artificial urinary sphincter placement, may be considered for patients who do not respond to conservative measures. A multidisciplinary approach involving urologists, neurologists, and rehabilitation specialists is essential to tailor the management plan to the individual patient's needs.

Keywords: Neurogenic bladder, evidence-based strategies, pharmacological interventions, anticholinergics, intermittent catheterization, patient education, self-management, lifestyle modifications, neuromodulation, multidisciplinary approach.

Introduction:

Neurogenic bladder, a condition resulting from the dysfunction of the bladder due to nerve-related injuries or diseases, presents significant clinical challenges that greatly affect patients' quality of life. The etiology of neurogenic bladder can range from congenital disorders, such as spina bifida, to acquired conditions such as multiple sclerosis, spinal cord injury, and neurological diseases like Parkinson's disease or diabetic neuropathy. The implications of this condition extend beyond urinary incontinence; they may lead to recurrent urinary tract infections, renal complications, and heightened psychological distress due to the lifestyle changes necessitated by the condition [1].

Research in recent years has increasingly focused on evidence-based strategies to manage neurogenic bladder effectively. These strategies are diverse, integrating pharmacological, non-pharmacological, and surgical interventions tailored to individual patient needs. Evidence-based medicine (EBM) emphasizes the use of the best current evidence in making decisions about the care of individual patients, merging clinical expertise with the most recent and relevant research findings. This approach is particularly crucial in the context of neurogenic bladder due to the heterogeneous nature of its presentations and underlying causes, as well as the variety of treatment options available [2].

The primary goal of managing neurogenic bladder is to restore normal bladder function or provide symptomatic relief while minimizing complications. Central to this management is a comprehensive assessment of bladder function, which typically includes urodynamic testing, a thorough evaluation of the patient's history, and a complete physical examination. Such assessments guide clinicians in selecting appropriate treatment modalities, ensuring that interventions align with the specific dysfunctions identified [3].

Within the realm of pharmacological management, anticholinergic medications, beta-3 agonists, and newer agents such as mirabegron represent important advancements in the treatment of neurogenic bladder symptoms, particularly in reducing urinary urgency and incontinence. These medications aim to enhance bladder storage capabilities while minimizing the risk of side effects. However, their efficacy can vary, and it may be essential to tailor therapeutic regimens to the individual patient's profile [4].

Non-pharmacological strategies also play a significant role in managing neurogenic bladder symptoms. Behavioral therapies, such as bladder training and pelvic floor muscle exercises, have shown efficacy in improving bladder control and enhancing the patient's ability to manage urinary symptoms proactively. Additionally, patient education and self-management strategies empower individuals to take an active role in their care, enabling them to make informed decisions based on their unique circumstances [5].

Surgical interventions may be warranted in cases where conservative therapies fail to provide adequate relief or when anatomical abnormalities contribute to bladder dysfunction. Procedures such as bladder augmentation, artificial urinary sphincter implantation, and sacral neuromodulation can significantly enhance bladder capacity and improve overall quality of life for certain patients. The choice of surgical technique must be grounded in a thorough understanding of the patient's specific condition, their preferences, and the potential risks and benefits associated with each option [6].

Moreover, the integration of multidisciplinary care teams is crucial in the management of neurogenic bladder. Urologists, neurologists, physical therapists, occupational therapists, and psychologists often collaborate to provide holistic treatment, addressing not only the physiological aspects of the condition but also the mental and emotional challenges faced by patients [7].

Etiology and Pathophysiology:

Neurogenic bladder refers to a dysfunction of the urinary bladder caused by a disorder of the nervous system, where the control of urination becomes impaired due to neurological damage. This condition can result from various etiological factors, including congenital defects, acquired injuries, or diseases affecting the central and peripheral nervous systems [8].

Etiology of Neurogenic Bladder

The etiology of neurogenic bladder can be categorized into two main types: congenital and acquired.

1. **Congenital Factors**: Congenital conditions refer to those present at birth. One of the most prevalent congenital causes of neurogenic bladder is spina bifida, a neural tube defect resulting in incomplete closure of the spine. This condition often leads to varying levels of paralysis and loss of bladder control. Other congenital disorders such as myelomeningocele also lead to sensory and motor nerve damage affecting bladder function [9].

2. **Acquired Factors**: Acquired causes include a wide range of neurological disorders and injuries. Common etiologies under this category include:
    - **Spinal Cord Injury (SCI)**: Traumatic injuries to the spinal cord can result in complete or incompletely paralysed states, leading to disruption in the normal bladder function. The level of injury determines the extent of impairment, with higher cervical injuries resulting in more extensive dysfunction.
    - **Multiple Sclerosis (MS)**: An autoimmune disease characterized by demyelination in the central nervous system. MS can impact bladder control through lesions in the spinal cord and brain, leading to both overactive bladder (OAB) and underactive bladder conditions.
    - **Stroke**: Damage to the areas of the brain that regulate bladder function can result in loss of bladder control. Stroke can lead to detrusor overactivity or decreased bladder compliance, significantly affecting voiding [10].
    - **Parkinson's disease**: The degeneration of dopaminergic neurons affects not only motor control but also involuntary functions, including bladder function. Patients often experience urgency and frequent urination [11].
    - **Diabetes**: Diabetic neuropathy can cause peripheral nerve damage, affecting several body systems, including the bladder. This results in a condition often referred to as diabetic cystopathy, leading to increased post-void residual volumes and urinary retention [11].

Pathophysiology of Neurogenic Bladder

The pathophysiological aspects of neurogenic bladder help to explain how the dysfunction in the urinary bladder occurs following neural injury or degeneration. The bladder's normal functions are governed by a complex interplay of neural mechanisms, involving both voluntary and involuntary control.

1. **Central Nervous System and Bladder Control**: The storage and voiding of urine are coordinated by the nervous system. The bladder is innervated by both sympathetic and parasympathetic pathways. The sympathetic nervous system, primarily through the hypogastric nerve, promotes bladder storage by contracting the internal urethral sphincter and relaxing the detrusor muscle. In contrast, the parasympathetic nervous system, via the pelvic nerve, facilitates urination by inducing detrusor contraction and sphincter relaxation. Neurological damage disrupts this balance, leading to either overactive or underactive bladder conditions [12].
2. **Overactive Bladder and Detrusor Overactivity**: In conditions like multiple sclerosis or spinal cord injuries above the S2-S4 level, detrusor overactivity is common. This results in involuntary bladder contractions during the filling phase, leading to urgency, frequency, and incontinence. Impaired inhibitory signals from the brain cause a pathological reflex mechanism, where despite the bladder being in a storage phase, it tries to empty uncontrollably [13].
3. **Underactive Bladder and Detrusor Areflexia**: Conversely, injuries to the sacral spinal cord or diseases like diabetes result in detrusor areflexia, leading to inadequate bladder contractions during the voiding phase. This causes urinary retention with an inability to empty the bladder completely, leading to complications such as urinary tract infections, bladder distention, and potential renal damage over time.

4. **Neuromuscular Changes**: The neuronal pathways responsible for bladder management also undergo physical and functional changes post-injury. In response to chronic overdistension or damage, the muscle and soft tissues may become fibrotic, the bladder wall may become less compliant, and the overall detrusor muscle contractility may start to decline. This results in a deterioration of both storage and voiding functions, exacerbating the symptoms associated with neurogenic bladder [14].

Assessment and Diagnosis:

Neurogenic bladder refers to a condition in which the bladder's function is impaired due to disturbances in the nervous system, leading to a variety of symptoms such as incontinence, urinary retention, or increased frequency and urgency. This condition can emanate from several underlying causes, including spinal cord injuries, multiple sclerosis, stroke, or traumatic brain injuries [15].

To appreciate the evaluation and diagnosis of neurogenic bladder, one must first comprehend the anatomy and physiology of the urinary system. The bladder, a muscular sac located in the pelvis, stores urine produced by the kidneys until it is expelled from the body. The process of urination involves a complex interplay of neurological signals that promote bladder contraction (via the parasympathetic nervous system) and sphincter relaxation. Disruptions in the nervous system can lead to an inability to control these functions, resulting in various bladder-related issues [16].

Symptoms of Neurogenic Bladder

Symptoms of neurogenic bladder can vary significantly depending on the underlying cause and may include:

1. **Urinary Incontinence:** An inability to control urination can lead to involuntary leakage of urine.
2. **Urinary Retention:** Patients may experience difficulty in emptying the bladder, resulting in distention and potential urinary tract infections (UTIs).
3. **Increased Urgency and Frequency:** Patients may feel an urgent need to urinate frequently, which can disrupt daily activities and quality of life [17].

These symptoms often necessitate urgent evaluation to determine the underlying cause and develop an appropriate treatment plan.

Initial Evaluation

The initial evaluation for suspected neurogenic bladder typically begins with a comprehensive patient history and physical examination. Clinicians will inquire about the patient's medical history, including any prior neurological issues, surgeries, or trauma that might have affected the nervous system. They will also assess urinary patterns, including frequency, volume, and any associated symptoms such as pain or incontinence [18].

Following the history and physical examination, several diagnostic tests may be employed to further evaluate bladder function and ascertain the underlying cause of any dysfunction.

Urodynamic Studies

Urodynamic studies are among the most vital diagnostic tests for evaluating neurogenic bladder. These tests assess how well the bladder, sphincters, and urethra store and release urine. Urodynamics involve measuring pressures within the bladder and urethra during bladder filling and emptying. Parameters such as bladder compliance, capacity, and detrusor pressure are evaluated to understand the bladder's functional characteristics better [19].

1. **Cystometry:** This test assesses bladder pressure during filling and helps determine if the bladder can accommodate urine without significant pressure increases, a crucial factor in assessing neurogenic bladder.
2. **Pressure Flow Study:** It evaluates the voiding phase by measuring the pressure in the bladder as the patient attempts to urinate, providing insight into bladder contractility and conditions leading to urinary retention.

3. **Electromyography (EMG):** This test evaluates the electrical activity of the pelvic floor muscles and sphincters during the voiding process, which can help identify issues in the nerve supply to these structures [19].

Imaging Studies

Imaging studies may also be employed in the evaluation of neurogenic bladder. Ultrasound is routinely used to visualize the anatomy of the bladder and kidneys and assess for post-void residual urine. In cases where structural abnormalities are suspected, additional imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scans may be utilized to assess the central nervous system [20].

For patients with suspected spinal cord abnormalities, MRI is particularly valuable as it allows for detailed visualization of the spinal column and can identify herniated discs, tumors, or other lesions that may be impeding normal nerve function.

Urinalysis is a common laboratory test performed as part of the initial evaluation. It can help identify urinary tract infections, hematuria (blood in urine), or other abnormalities. In some cases, culture and sensitivity tests might be conducted to identify the specific organisms responsible for a UTI, guiding antibiotic therapy.

Additionally, blood tests may be indicated to assess renal function and detect underlying conditions that may contribute to bladder dysfunction, such as diabetes mellitus that may lead to diabetic neuropathy affecting bladder control [21].

The evaluation process may also incorporate assessments of comorbid conditions that could exacerbate or contribute to symptoms of neurogenic bladder. For example, conditions like diabetes, obesity, or pelvic organ prolapse may complicate diagnosis and treatment.

Due to the complexity of bladder dysfunction and the varying presentation of symptoms, a differential diagnosis is essential. Conditions such as bladder outlet obstruction, detrusor overactivity, or even some infectious processes can mimic symptoms of neurogenic bladder. Clinicians must rule out other potential causes to implement an effective management plan [22].

Pharmacological Management:

Neurogenic bladder is a condition characterized by the loss of voluntary control over the bladder due to a neurological condition, injury, or disease that impacts the bladder's nerve supply. This dysfunction can lead to urinary retention, incontinence, and significant deterioration in the quality of life for affected individuals. Management of neurogenic bladder often involves a multifaceted approach, including behavioral therapies, catheterization, surgical interventions, and pharmacological treatments. Among these, pharmacological management plays a pivotal role in optimizing bladder function and alleviating symptoms [23].

Neurogenic bladder arises from a variety of conditions, including spinal cord injuries, multiple sclerosis, Parkinson's disease, diabetes, and other neurological disorders. The normal bladder's function relies on a complex interplay of neurological inputs that coordinate the storage and expulsion of urine through involuntary and voluntary mechanisms. Damage to the central or peripheral nervous system disrupts these signals, leading to a spectrum of urinary symptoms such as spastic bladder (overactive bladder), flaccid bladder (underactive bladder), or a combination of both [24].

The clinical presentation of neurogenic bladder can vary widely, typifying the need for individualized treatment plans. Symptoms can include frequent urination, urgency, nocturia, urge incontinence, and urinary retention, with profound impacts on personal hygiene, emotional well-being, and overall life satisfaction [25].

Pharmacological Strategies

Evidence-based pharmacotherapy for neurogenic bladder focuses on restoring bladder function, minimizing complications, and improving patients' quality of life. Key pharmacological agents used in the management of neurogenic bladder include anticholinergics, beta-3 agonists, and certain off-label medications. The choice of pharmacological intervention often reflects the specific type of neurogenic bladder and the patient's overall medical condition [26].

1. **Anticholinergics**:
   Anticholinergic agents, including oxybutynin, tolterodine, and solifenacin, act primarily by inhibiting acetylcholine's action at muscarinic receptors in the bladder. This leads to a reduction in bladder detrusor activity, effectively alleviating symptoms associated with overactive bladder (OAB) conditions, such as urgency and frequent urination. Numerous studies indicate that these medications significantly decrease the frequency of incontinence episodes and improve bladder capacity. For instance, a systematic review that analyzed multiple randomized controlled trials found that anticholinergics significantly reduce the number of urinations and incontinence episodes, thereby enhancing quality of life [27].

2. **Beta-3 Agonists**:
   Mirabegron, a relatively newer addition to the pharmacological armamentarium, is a beta-3 adrenergic agonist that promotes relaxation of the detrusor muscle during bladder filling. This mechanism contrasts with that of anticholinergics, and studies suggest that mirabegron is efficacious for patients who either experience intolerable side effects with anticholinergics or have contraindications for their use. The results from a multicenter trial showed that mirabegron is effective in reducing urinary incontinence episodes while displaying a favorable side effect profile, specifically, a lower incidence of dry mouth compared to anticholinergics [28].

3. **Off-Label Medications**:
   Certain medications, although not primarily indicated for bladder management, have shown efficacy in treating neurogenic bladder symptoms. For example, the tricyclic antidepressant amitriptyline has been recognized for its anticholinergic properties and its utility in managing neuropathic pain. This dual effect can be particularly beneficial for patients with bladder dysfunction linked to underlying neurological conditions. Further research and clinical evidence are needed to specify dosages and treatment regimens for off-label drugs in this context [29].

4. **Combination Therapy**:
   In some patients, particularly those with complex presentations, combined pharmacological regimens may be warranted. For instance, implementing both an anticholinergic and a beta-3 agonist can provide a synergistic effect, potentially leading to improved outcomes regarding bladder control and quality of life. Clinical guidelines support personalized treatment approaches, emphasizing the importance of careful assessment and monitoring of patients' responses to pharmacological agents [30].

Potential Risks and Side Effects

While pharmacological management offers valuable benefits, it is critical to consider potential risks and side effects. Anticholinergic medications, for example, can induce cognitive side effects, particularly in older adults, leading to concerns about their long-term use. These could include impaired memory, confusion, and an increased risk of falls. Moreover, caution should be exercised in patients with comorbidities such as glaucoma or urinary retention due to prostate enlargement [31].

Beta-3 agonists generally have a superior side effect profile, with the most common complaints usually relating to increased blood pressure. Therefore, baseline hypertension screening and ongoing monitoring in patients on mirabegron remain essential.

Ongoing research is vital in refining and improving the pharmacological management of neurogenic bladder. Emerging therapies are being explored, including neuromodulation techniques, gene therapy, and novel pharmacological agents targeting specific pathways in the bladder's neural circuitry. Evidence supporting these innovations will be necessary to establish their therapeutic roles further [31].

Non-Pharmacological Interventions:

Neurogenic bladder is a condition characterized by the loss of bladder control due to a neurological disorder. It commonly arises from conditions affecting the central or peripheral nervous system, such as spinal cord injuries, multiple sclerosis, stroke, or diabetic neuropathy. The consequences can include urinary incontinence, urinary retention, frequent urination, and increased risk of urinary tract infections. While pharmacological treatments, such as anticholinergics and beta-3 adrenergic agonists, are widely used, non-pharmacological interventions have become essential components of management strategies for neurogenic bladder [32].

Behavioral therapies encompass a range of approaches that aim to alter bladder habits and improve control over urinary function. One of the most popular methods is bladder training, which involves scheduled voiding and gradually increasing intervals between bathroom visits. This technique can help individuals regain control over their bladder and reduce episodes of incontinence. Patients start by toileting at predetermined times, then gradually extend these intervals as their bladder capacity increases. This method has shown positive results in improving bladder function and patient quality of life [33].

In conjunction with bladder training, prompted voiding can be employed, particularly for patients with cognitive impairments. Caregivers are trained to prompt individuals to use the bathroom at regular intervals, which aids in preventing accidents. This dual approach supports behavioral modification and creates a supportive environment for those with neurogenic bladder [34].

Additionally, cognitive-behavioral therapy (CBT) can be addressed, focusing on the psychological factors associated with bladder control, such as anxiety and embarrassment related to incontinence. CBT aims to reduce avoidance behaviors and encourage adaptive coping strategies, helping patients build confidence in managing their condition [35].

Pelvic floor exercises, commonly referred to as Kegel exercises, target the muscles of the pelvic floor and aim to improve urinary control. Strengthening these muscles can enhance support for the bladder and urethra, potentially reducing instances of urinary incontinence. For individuals with neurogenic bladder, these exercises can be especially beneficial when taught in conjunction with biofeedback, a process that provides real-time information about muscle contraction and relaxation techniques [36].

A physical therapist specializing in pelvic health can design individualized exercise programs, guiding patients on proper techniques and progressions. Studies have shown that adherence to a regular pelvic floor exercise regimen can significantly improve bladder function and decrease urinary incontinence episodes [37].

Electrostimulation therapies involve the application of electrical currents to stimulate the nerves associated with bladder function. This technique can modulate nerve activity, which may improve bladder sensation and storage capacity. One method, sacral nerve stimulation (SNS), has been used effectively in cases of refractory urge urinary incontinence and bladder dysfunction. SNS involves implanting a small device that sends pulsed electrical signals to the sacral nerves, which can help regulate bladder function by improving communication between the bladder and the brain [38].

Transcutaneous electrical nerve stimulation (TENS) is another non-invasive alternative that offers similar benefits without surgical intervention. TENS applies electrical impulses via electrodes placed on the skin over the bladder area. While still under research, preliminary findings suggest a positive impact on bladder control and a reduction of overactive bladder symptoms [39].

Dietary modifications play a critical role in managing neurogenic bladder symptoms. Staying well-hydrated while avoiding excessive fluid intake in late hours can mitigate the risk of nocturia (nighttime urination) or subsequent incontinence. It is also beneficial to monitor and possibly limit the intake of bladder irritants, such as caffeine, alcohol, carbonated beverages, and acidic foods, which can exacerbate urinary urgency and frequency [39].

Moreover, maintaining a healthy body weight is crucial, as obesity can increase abdominal pressure and exacerbate bladder dysfunction. Implementing a balanced diet alongside regular physical activities that do not strain the bladder can enhance overall

health and yield better bladder management outcomes [40].

For individuals with urinary retention, catheterization may be necessary. Teaching self-catheterization or using intermittent catheterization as a management strategy is vital. This may involve educating patients about sterile techniques, prevention of urinary tract infections, and proper care of catheters. When individuals become adept in their catheter care, it can significantly improve their quality of life and reduce complications.

The modern age has birthed various supportive technologies aimed at enhancing the management of neurogenic bladder. Smart toilet systems equipped with sensors can aid in bladder monitoring, providing users with feedback on their urinary patterns. Mobile health apps that track fluid intake and voiding habits can also empower patients to take control of their bladder health. Such technological advancements assist in remote monitoring and can be shared with healthcare professionals for comprehensive care [41].

Patient Education and Self-Management Strategies:

Neurogenic bladder is a condition marked by the loss of normal bladder function due to a dysfunction in the neural pathways that control bladder storage and emptying. This condition can arise from various neurological disorders, such as multiple sclerosis, spinal cord injury, stroke, and other conditions that affect the nervous system. As neurogenic bladder can lead to significant complications, including urinary tract infections, incontinence, and reduced quality of life, patient education and self-management strategies are essential components of care [42].

The first step in managing neurogenic bladder is understanding the mechanics of normal bladder function. The bladder stores urine and signals through the nervous system when it is full. In individuals with neurogenic bladder, interruptions in this signaling can lead to various patterns of dysfunction, including overactive bladder, underactive bladder, and mixed forms. The severity of symptoms can range from mild inconvenience to severe complications and require a tailored approach to management.

Patient education serves as a cornerstone for effective management. It empowers patients with knowledge about their condition, underlying causes, and potential consequences. This understanding helps patients recognize symptoms early, comprehend the importance of routine monitoring and follow-ups, and appreciate the significance of compliance with prescribed strategies and treatments [43].

Importance of Patient Education

Patient education encompasses a variety of information, including anatomical knowledge, pathophysiology of the condition, and the implications of neurogenic bladder on daily life. Effective education is crucial for several reasons:

1. **Informed Decision-Making:** Educated patients can make informed decisions regarding their treatment options, lifestyle choices, and management strategies. This knowledge can promote a sense of autonomy in managing their health [44].
2. **Enhanced Compliance:** When patients understand the importance of medications, self-catheterization, or bladder training, they are more likely to adhere to treatment plans.
3. **Symptom Recognition:** Education equips patients to recognize and report symptoms early, potentially preventing complications such as urinary tract infections and renal damage [44].
4. **Psychosocial Support:** Learning about the emotional and psychological impacts of neurogenic bladder can help patients seek appropriate support, whether through counseling, support groups, or community resources.
5. **Relieving Fear and Anxiety:** Knowledge of the condition and effective management techniques can help alleviate fears related to incontinence or bladder dysfunction [45].

Self-Management Strategies

Patients can utilize a variety of self-management strategies tailored to their individual needs and the specifics of their neurogenic bladder. Here are some key approaches:

1. **Bladder Training Regimens:** Bladder training can help patients regain control over their bladder function. This method involves setting a schedule for bladder emptying to gradually increase the intervals between voiding. This approach is beneficial for patients with an overactive bladder [46].
2. **Timed Voiding or Scheduled Toilet Use:** This strategy includes voiding at regular intervals, even if the individual does not feel the urge to urinate. Timed voiding helps to prevent accidents and maintain skin integrity, an important consideration for those at risk of skin breakdown [46].
3. **Self-Catheterization:** For individuals with underactive bladder or those unable to empty their bladder completely, self-catheterization can be a critical tool. Training on proper techniques and hygiene practices helps prevent infection and ensures effective bladder management [47].
4. **Pelvic Floor Muscle Training:** Strengthening pelvic floor muscles through physical therapy can aid individuals experiencing stress incontinence. Engaging in pelvic floor exercises, such as Kegel exercises, can improve bladder control and reduce leakage.
5. **Fluid Management:** Patients need to monitor their fluid intake to avoid dehydration or overhydration, both of which can exacerbate symptoms. A healthcare provider can help establish an appropriate fluid intake schedule according to individual needs and urinary output [48].
6. **Dietary Considerations:** Certain foods and beverages can irritate the bladder. Educating patients about potential urinary irritants, such as caffeine, alcohol, and acidic foods, can assist them in making dietary choices that promote bladder health.
7. **Medication Management:** Patients often benefit from education on the various medications used to manage symptoms of neurogenic bladder, including anticholinergics, beta-3 adrenergic agonists, and topical estrogen. Understanding the purpose and side effects of these medications fosters compliance and reduces anxiety regarding their use [48].
8. **Utilizing Technology:** With advancements in mobile health (mHealth) technology, patients can benefit from applications that remind them of scheduled voiding, track fluid intake, and log bladder habits. These tools empower patients with additional resources for managing their condition [48].

The Role of Healthcare Providers

Healthcare providers play a pivotal role in the education and management of patients with neurogenic bladder. They must first assess the specific type of neurogenic bladder the patient is experiencing, considering factors such as neurological status, overall health, and individual preferences. Providers can develop personalized education and management plans that take into account the diverse nature of symptoms and the variation in patient responses to treatment.

1. **Multidisciplinary Approach:** Involving urologists, neurologists, nurses, physical therapists, and other healthcare professionals ensures a comprehensive understanding of the condition and its implications. Collaboration across disciplines can provide a more holistic approach to patient management [49].
2. **Ongoing Support and Follow-Up:** Healthcare providers should schedule regular follow-ups to assess the effectiveness of self-management strategies, provide ongoing education, and

make timely adjustments to treatment plans when necessary. Support groups can also be recommended to foster community among patients.

3. **Empathy and Cultural Sensitivity:** Addressing concerns empathetically and recognizing cultural differences in responses to medical education and management strategies can significantly enhance patient engagement and compliance [50].

Advanced Therapeutic Options:

Neurogenic bladder is a condition resulting from dysfunction in the bladder and its neural control, often caused by neurological disorders such as spinal cord injury, multiple sclerosis, Parkinson's disease, and cerebral palsy. Individuals afflicted with this condition experience varying degrees of urinary incontinence, retention, and storage or emptying difficulties, significantly impacting their quality of life. Traditional management strategies like lifestyle adjustments and pharmacological treatments may not be sufficient for all patients, necessitating exploration of more advanced treatment options [51].

1. Neuromodulation Techniques

Neuromodulation is one of the most promising advances in the treatment of neurogenic bladder. This approach involves altering nerve activity through targeted electrical stimulation. There are two key types of neuromodulation techniques currently being utilized: sacral nerve stimulation (SNS) and posterior tibial nerve stimulation (PTNS).

Sacral Nerve Stimulation (SNS): SNS involves implanting a small device that sends electrical impulses to the sacral nerves, which control bladder function. The therapy aims to restore normal bladder function by modulating the nerve pathways involved in bladder storage and emptying. Clinical studies have shown that SNS can effectively reduce urinary incontinence and increase bladder capacity, with many patients reporting significant improvements in their quality of life. However, the procedure may involve risks such as infection or device malfunction, and it requires a surgical intervention for implantation [52].

Posterior Tibial Nerve Stimulation (PTNS): PTNS is a less invasive neuromodulation technique that stimulates the tibial nerve at the ankle, indirectly affecting the sacral plexus. This outpatient procedure generally involves a series of approximately 12 weekly sessions. Although it has shown effectiveness similar to SNS in certain studies, it may require ongoing maintenance treatments after the initial therapy to sustain its benefits. The primary advantage of PTNS is its minimally invasive nature, making it a more accessible option for individuals who may not be candidates for surgical interventions [53].

2. Intravesical Therapies

Intravesical treatments involve the direct delivery of therapeutic agents into the bladder, providing localized medication effects. Among these, Botox injections and the use of anticholinergic agents are gaining traction.

Botulinum Toxin (Botox): Administering Botox intravesically has emerged as a highly effective alternative for managing neurogenic bladder symptoms, particularly in cases characterized by detrusor overactivity. Botox works by blocking the release of acetylcholine, which decreases involuntary bladder contractions and enhances bladder capacity. Studies have reported favorable outcomes, with a substantial number of patients experiencing significant improvement in urinary frequency and urgency. However, the effects are temporary, typically lasting around six to nine months, necessitating repeat treatments. Furthermore, potential side effects such as urinary retention may occur, requiring careful patient selection and monitoring [54].

Anticholinergic Agents: While primarily used in oral form, intravesical delivery systems for anticholinergic drugs are being explored to mitigate overactive bladder symptoms in patients with neurogenic origins. These drugs work by inhibiting cholinergic receptor activity, reducing involuntary contractions. Yet, systemic side effects, including dry mouth and blurred vision, may limit their use in a broader context. Ongoing research into improving drug delivery systems continues to assess efficacy and minimize adverse effects [55].

3. Surgical Interventions

For some patients with neurogenic bladder, surgical interventions may provide definitive management. Procedures can include bladder augmentation, urinary diversion, or artificial sphincter implantation [55].

Bladder Augmentation: This surgical technique involves enlarging the bladder, usually by using a segment of the intestine. By increasing bladder capacity and compliance, patients may experience fewer incontinence episodes. However, this procedure carries risks associated with bowel function alteration, urinary tract infections, and potential complications associated with bowel materials used.

Urinary Diversion: In cases where the bladder function is severely impaired, urinary diversion may be necessary. This can involve creating a new conduit for urine to exit the body, either through an external stoma or by constructing a neobladder from intestinal tissue. While these procedures may improve patient outcomes, they involve significant lifestyle adjustments and require comprehensive pre-operative counseling.

Artificial Urinary Sphincter: This device is implanted in male patients experiencing severe incontinence. The device functions by using a cuff placed around the urethra, which can be inflated or deflated to maintain urinary continence. It has shown significant success in restoring control, but ongoing maintenance and the need for surgical intervention to manage device complications pose potential drawbacks [56].

4. Expanded Pharmacological Options

Pharmacotherapy in neurogenic bladder treatment has evolved, with new agents and combinations being explored. Alpha-blockers and beta-3 adrenergic agonists are among the emerging options.

Alpha-Blockers: Primarily used to treat urinary retention, alpha-blockers act by relaxing smooth muscle in the bladder neck and prostate, facilitating urinary flow. This medication may be particularly useful for patients with neurogenic bladder associated with benign prostatic hyperplasia [57].

Beta-3 Adrenergic Agonists: Recently approved, beta-3 adrenergic agonists help to relax the detrusor muscle, facilitating bladder filling and reducing episodic contractions. These agents have shown promise in both safety and efficacy compared to traditional anticholinergic therapies, potentially offering a more favorable side effect profile [58].

Multidisciplinary Care and Future Directions:

Neurogenic bladder is a condition characterized by a dysfunction of the urinary bladder that arises from nervous system abnormalities. This condition can result from various causes, including spinal cord injuries, multiple sclerosis, Parkinson's disease, cerebrovascular accidents (strokes), and congenital disorders like spina bifida. The symptoms may vary from urinary incontinence and urinary retention to recurrent urinary tract infections (UTIs) and diminished quality of life. Given the complex interplay between the urinary system and the nervous system, managing neurogenic bladder effectively necessitates a multidisciplinary care approach [59].

Understanding Neurogenic Bladder

The bladder's ability to store and expel urine is heavily dependent on neurological signals. Any disruption in these signals can significantly impact bladder function. For instance, spinal cord injuries can lead to a loss of voluntary bladder control, causing patients to either leak urine involuntarily or retain urine in the bladder, leading to distention and other complications. Diagnosing neurogenic bladder typically involves a comprehensive clinical evaluation along with urodynamic studies, which assess how well the bladder and urethra are functioning [60].

The Multidisciplinary Approach

Managing neurogenic bladder is not solely within the purview of urologists; it requires the collaborative efforts of various healthcare professionals. A multidisciplinary care team may include:

1. **Urologists**: Often the primary practitioners, they conduct diagnostics and treatments, including pharmacological options, catheterization techniques, and

surgical interventions such as bladder augmentation or sphincter applications.

2. **Neurosurgeons**: They may be involved in cases resulting from spinal cord injuries or neurological disorders requiring surgical intervention to ease pressure on the nerves.
3. **Rehabilitation Specialists**: Physical and occupational therapists are crucial for helping patients regain functional independence and adapt to lifestyle changes necessitated by neurogenic bladder [61].
4. **Nurses**: Specialized nurses often provide education on self-catheterization techniques, urinary tract infection prevention, and general care for patients with chronic conditions.
5. **Psychologists/Psychiatrists**: These professionals address the mental health aspects associated with living with chronic conditions, providing coping strategies for anxiety and depression which may arise from the challenges of managing a neurogenic bladder.
6. **Nutritionists**: They can help in managing dietary habits that may promote a healthy urinary system, thereby reducing the likelihood of complications from neurogenic bladder [62].

The collaborative framework around neurogenic bladder care is essential in delivering comprehensive health management. It helps ensure that all aspects of the patient's health are considered, potentially improving outcomes and overall quality of life.

Treatment Modalities

There are numerous treatment options for managing neurogenic bladder, which are typically tailored to the patient's specific condition and symptoms. These include:

1. **Medications**: Anticholinergic medications can help relieve symptoms by reducing bladder spasms, while beta-3 adrenergic agonists may enhance bladder capacity. For those experiencing urinary retention, medications to stimulate bladder contractions may be prescribed [62].
2. **Catheterization**: Intermittent catheterization is often the standard treatment to ensure complete bladder emptying and prevent urinary retention or UTIs. In cases where patients cannot do this independently, indwelling catheters can be employed, albeit with caution about infection risks.
3. **Surgical Procedures**: Options such as bladder augmentation, insertion of an artificial urinary sphincter, or even sacral neuromodulation are considered based on the severity of the condition and the patient's overall health status [63].
4. **Lifestyle and Behavioral Interventions**: Timed voiding and bladder training can also be effective, especially in patients with some remaining bladder function [63].

Future Directions in Neurogenic Bladder Management

The management of neurogenic bladder is continually evolving, driven by advances in medical technology, research, and a greater understanding of the underlying pathophysiology. Some promising future directions include:

1. **Telemedicine**: The increasing use of telemedicine can enhance patient follow-up, providing remote consultations that can improve access to care and monitoring without the need for physical office visits.
2. **Emerging Therapies**: Ongoing research into stem cell therapy and regenerative medicine may provide new avenues for repairing nerve damage and restoring bladder function. Although these treatments are still in experimental stages, they hold promise for the future [64].
3. **Neurotechnology**: Innovations such as bioelectronic devices that modulate nerve signals can potentially offer new treatment

modalities that are less invasive and more effective. These technologies involve stimulating or inhibiting neural pathways responsible for bladder function, which could lead to improvements in symptoms.

4. **Personalized Medicine**: As our understanding of genetic and epigenetic factors associated with neurogenic bladder improves, individualized treatment plans may become feasible. This could allow healthcare providers to target therapies more effectively based on a patient's unique biological makeup [64].

5. **Increased Patient Education and Support**: Enhancing patient education initiatives concerning self-management strategies and the importance of routine follow-up could empower patients and improve outcomes [65].

Conclusion:

In conclusion, the management of neurogenic bladder requires a nuanced, evidence-based approach that encompasses a variety of pharmacological, non-pharmacological, and advanced interventions tailored to the individual needs of each patient. By understanding the underlying etiology and pathophysiology, clinicians can accurately assess and diagnose the condition, ensuring appropriate treatment strategies are implemented. Pharmacological options, including anticholinergics and cholinergic agents, play a critical role in managing symptoms, while non-pharmacological approaches such as bladder training, pelvic floor exercises, and lifestyle modifications enhance patient quality of life.

Moreover, patient education and self-management are essential components of effective care, empowering individuals to take an active role in their bladder health. The consideration of advanced therapeutic options like neuromodulation and surgical interventions may be necessary for patients with refractory symptoms. A multidisciplinary approach that includes urologists, neurologists, and rehabilitation specialists is crucial for optimizing outcomes and addressing the complex needs of patients with neurogenic bladder. With ongoing research and advancements in treatment modalities, there is potential for improved management strategies that enhance the overall quality of life for affected individuals.

References:

1. Krassioukov A., Linsenmeyer T.A., Beck L.A., Elliott S., Gorman P., Kirshblum S., Vogel L., Wecht J., Clay S. Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows: Management of Blood Pressure, Sweating, and Temperature Dysfunction. Top. Spinal Cord Inj. Rehabil. 2021;27:225–290. doi: 10.46292/sci2702-225.
2. Eschlböck S., Wenning G., Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J. Neural. Transm. 2017;124:1567–1605. doi: 10.1007/s00702-017-1791-y.
3. Linsenmeyer T.A., Gibbs K., Solinsky R. Autonomic Dysreflexia After Spinal Cord Injury: Beyond the Basics. Curr. Phys. Med. Rehabil. Rep. 2020;8:443–451. doi: 10.1007/s40141-020-00300-5.
4. Clark C.B., Ragam R., Das A.K., Shenot P.J. Management of neurogenic detrusor overactivity. Can. J. Urol. 2021;28:33–37.
5. Ginsberg D.A., Boone T.B., Cameron A.P., Gousse A., Kaufman M.R., Keays E., Kennelly M.J., Lemack G.E., Rovner E.S., Souter L.H., et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. J. Urol. 2021;206:1097–1105. doi: 10.1097/JU.0000000000002235.
6. Dodd W., Motwani K., Small C., Pierre K., Patel D., Malnik S., Lucke-Wold B., Porche K. Spinal cord injury and neurogenic lower urinary tract dysfunction: What do we know and where are we going? J. Men's Health. 2022;18:6. doi: 10.31083/j.jomh1801024.
7. Ginsberg D.A., Boone T.B., Cameron A.P., Gousse A., Kaufman M.R., Keays E., Kennelly M.J., Lemack G.E., Rovner E.S., Souter L.H., et al. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and

Follow-up. J. Urol. 2021;206:1106–1113. doi: 10.1097/JU.0000000000002239.
8. Wecht J.M., Krassioukov A.V., Alexander M., Handrakis J.P., McKenna S.L., Kennelly M., Trbovich M., Biering-Sorensen F., Burns S., Elliott S.L., et al. International Standards to document Autonomic Function following SCI (ISAFSCI): Second Edition. Top. Spinal Cord Inj. Rehabil. 2021;27:23–49. doi: 10.46292/sci2702-23.
9. Rahman M., Siddick A. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2021. Neuroanatomy, Pontine Micturition Center. Updated 9 September 2021.
10. Jain N.B., Ayers G.D., Peterson E.N., Harris M.B., Morse L., O'Connor K.C., Garshick E. Traumatic spinal cord injury in the United States, 1993–2012. JAMA. 2015;313:2236–2243. doi: 10.1001/jama.2015.6250.
11. Lim V., Mac-Thiong J.M., Dionne A., Begin J., Richard-Denis A. Clinical Protocol for Identifying and Managing Bladder Dysfunction during Acute Care after Traumatic Spinal Cord Injury. J. Neurotrauma. 2021;38:718–724. doi: 10.1089/neu.2020.7190.
12. Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the neuropathic bladder in spinal cord injured patients. Spinal Cord. 2001;39:294–300. doi: 10.1038/sj.sc.3101160.
13. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205–209. doi: 10.1016/s0022-5347(17)54449-3.
14. Dmochowski R. Neuro-urology. New York, NY: Springer Berlin Heidelberg; 2018.
15. Costa Monteiro LM, Cruz GO, Fontes JM et al. Early treatment improves urodynamic prognosis in neurogenic voiding dysfunction: 20 years of experience. J Pediatr (Rio J) 2017;93:420–427. doi: 10.1016/j.jped.2016.11.010.
16. Averbeck MA, Madersbacher H. Follow-up of the neuro-urological patient: A systematic review. BJU Int. 2015;115(Suppl 6):39–46. doi: 10.1111/bju.13084.
17. Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int. 2006;98:739–745. doi: 10.1111/j.1464-410X.2006.06395.x.
18. Welk B, Schneider MP, Thavaseelan J, Traini LR, Curt A, Kessler TM. Early urological care of patients with spinal cord injury. World J Urol. 2018;36:1537–1544. doi: 10.1007/s00345-018-2367-7.
19. Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: A four-phase model. Spinal Cord. 2004;42:383–395. doi: 10.1038/sj.sc.3101603.
20. Cardenas DD, Kelly E, Mayo ME. Manual stimulation of reflex voiding after spinal cord injury. Arch Phys Med Rehabil. 1985;66:459–462.
21. Bauer SB, Hallett M, Khoshbin S et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA. 1984;252:650–652.
22. Steinhardt GF, Goodgold HM, Samuels LD. The effect of intravesical pressure on glomerular filtration rate in patients with myelomeningocele. J Urol. 1988;140:1293–1295. doi: 10.1016/s0022-5347(17)42028-3.
23. Trust EF, Lange R, Becker A, Braun J. Urodynamics in clinical practice. Urol Clin North Am. 1996;23:319–341. doi: 10.1016/s0094-0143(05)70019-3.
24. Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: Comparison with the long-term living paraplegic. J Urol. 1977;117:486–488. doi: 10.1016/s0022-5347(17)58506-7.
25. Bywater M, Tornic J, Mehnert U, Kessler TM. Detrusor acontractility after acute spinal cord injury-myth or reality? J Urol. 2018;199:1565–1570. doi: 10.1016/j.juro.2018.01.046.
26. Wang SC, McGuire EJ, Bloom DA. A bladder pressure management system for myelodysplasia–clinical outcome. J Urol. 1988;140:1499–1502. doi: 10.1016/s0022-5347(17)42084-2.

27. Kim YH, Kattan MW, Boone TB. Bladder leak point pressure: The measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. J Urol. 1998;159:493–496. doi: 10.1016/s0022-5347(01)63957-0. discussion 6–7.
28. Eswara JR, Castellan M, Gonzalez R, Mendieta N, Cendron M. The urological management of children with spinal cord injury. World J Urol. 2018;36:1593–1601. doi: 10.1007/s00345-018-2433-1.
29. Blok B. Neuroanatomy relevant for the urologist. In: Dmochowski R, editor. Neuro-Urology. Cham, Switzerland: Springer International; 2018. pp. 3–12.
30. Stoffel JT. Detrusor sphincter dyssynergia: A review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5:127–135. doi: 10.3978/j.issn.2223-4683.2016.01.08.
31. Hopps CV, Kropp KA. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol. 2003;169:305–308. doi: 10.1016/S0022-5347(05)64112-2.
32. Ismail S., Karsenty G., Chartier-Kastler E., Cussenot O., Compérat E., Rouprêt M., Phé V. Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. Neurourol. Urodyn. 2018;37:1386–1395. doi: 10.1002/nau.23457.
33. Welk B., Schneider M.P., Thavaseelan J., Traini L.R., Curt A., Kessler T.M. Early urological care of patients with spinal cord injury. World J. Urol. 2018;36:1537–1544. doi: 10.1007/s00345-018-2367-7.
34. Greenstein A., Rucker K.S., Katz P.G. Voiding by increased abdominal pressure in male spinal cord injury patients--long term follow up. Paraplegia. 1992;30:253–255. doi: 10.1038/sc.1992.64.
35. Madhuvrata P., Singh M., Hasafa Z., Abdel-Fattah M. Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis. Eur. Urol. 2012;62:816–830. doi: 10.1016/j.eururo.2012.02.036.
36. Panicker J.N., Fowler C.J., Kessler T.M. Lower urinary tract dysfunction in the neurological patient: Clinical assessment and management. Lancet Neurol. 2015;14:720–732. doi: 10.1016/S1474-4422(15)00070-8.
37. Abrams P., Amarenco G., Bakke A., Buczyński A., Castro-Diaz D., Harrison S., Kramer G., Marsik R., Prajsner A., Stöhrer M., et al. Tamsulosin: Efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J. Urol. 2003;170:1242–1251. doi: 10.1097/01.ju.0000084623.65480.f8.
38. Kinnear N., Barnett D., O'Callaghan M., Horsell K., Gani J., Hennessey D. The impact of catheter-based bladder drainage method on urinary tract infection risk in spinal cord injury and neurogenic bladder: A systematic review. Neurourol. Urodyn. 2020;39:854–862. doi: 10.1002/nau.24253.
39. Cameron A.P., Wallner L.P., Tate D.G., Sarma A.V., Rodriguez G.M., Clemens J.Q. Bladder management after spinal cord injury in the United States 1972 to 2005. J. Urol. 2010;184:213–217. doi: 10.1016/j.juro.2010.03.008.
40. Guo W.B., Shapiro K., Wang Z.X., Armann K., Shen B., Wang J.C., Roppolo J.R., de Groat W.C., Tai C.F. Restoring both continence and micturition after chronic spinal cord injury by pudendal neuromodulation. Exp. Neurol. 2021;340:10. doi: 10.1016/j.expneurol.2021.113658.
41. Romo P.G.B., Smith C.P., Cox A., Averbeck M.A., Dowling C., Beckford C., Manohar P., Duran S., Cameron A.P. Non-surgical urologic management of neurogenic bladder after spinal cord injury. World J. Urol. 2018;36:1555–1568. doi: 10.1007/s00345-018-2419-z.
42. English S.F. Update on voiding dysfunction managed with suprapubic catheterization. Transl. Androl. Urol. 2017;6:S180–S185. doi: 10.21037/tau.2017.04.16.
43. Joshi A.D., Shukla A., Chawathe V., Gaur A.K. Clean intermittent catheterization in

long-term management of neurogenic bladder in spinal cord injury: Patient perspective and experiences. Int. J. Urol. 2022;19:317–323. doi: 10.1111/iju.14776.
44. Groah S.L., Weitzenkamp D.A., Lammertse D.P., Whiteneck G.G., Lezotte D.C., Hamman R.F. Excess risk of bladder cancer in spinal cord injury: Evidence for an association between indwelling catheter use and bladder cancer. Arch. Phys. Med. Rehabil. 2002;83:346–351. doi: 10.1053/apmr.2002.29653.
45. Hunter K.F., Bharmal A., Moore K.N. Long-term bladder drainage: Suprapubic catheter versus other methods: A scoping review. Neurourol. Urodyn. 2013;32:944–951. doi: 10.1002/nau.22356.
46. Lloyd L.K., Kuhlemeier K.V., Fine P.R., Stover S.L. Initial bladder management in spinal cord injury: Does it make a difference? J. Urol. 1986;135:523–527. doi: 10.1016/S0022-5347(17)45720-X.
47. Perkash I. Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. J.
48. Neurogenic Bladder Turkish Research Group. Yildiz N, Akkoc Y et al. Neurogenic bladder in patients with traumatic spinal cord injury: Treatment and follow-up. Spinal Cord. 2014;52:462–467. doi: 10.1038/sc.2014.41.
49. Vaidyanathan S, Selmi F, Hughes PL, Singh G, Soni BM. Urinary retention and acute kidney injury in a tetraplegic patient using condom catheter after partying: A preventable complication. Int Med Case Rep J. 2015;8:241–245. doi: 10.2147/IMCRJ.S86295.
50. Bray L, Sanders C. Teaching children and young people intermittent self-catheterization. Urol Nurs. 2007;27:203–209.
51. Roth JD, Pariser JJ, Stoffel JT et al. Patient subjective assessment of urinary tract infection frequency and severity is associated with bladder management method in spinal cord injury. Spinal Cord. Published online ahead of print March 14, 2019.
52. Madden-Fuentes RJ, McNamara ER, Lloyd JC et al. Variation in definitions of urinary tract infections in spina bifida patients: A systematic review. Pediatrics. 2013;132:132–139. doi: 10.1542/peds.2013-0557.
53. Trautner BW, Grigoryan L, Petersen NJ et al. Effectiveness of an antimicrobial stewardship approach for urinary catheter-associated asymptomatic bacteriuria. JAMA Intern Med. 2015;175:1120–1127. doi: 10.1001/jamainternmed.2015.1878.
54. Saint S, Kaufman SR, Rogers MA, Baker PD, Ossenkop K, Lipsky BA. Condom versus indwelling urinary catheters: A randomized trial. J Am Geriatr Soc. 2006;54:1055–1061. doi: 10.1111/j.1532-5415.2006.00785.x.
55. Oakeshott P, Hunt GM. Intermittent self-catheterization for patients with urinary incontinence or difficulty emptying the bladder. Br J Gen Pract. 1992;42:253–255.
56. Jabbour Y, Abdoulazizi B, Karmouni T, El Khader K, Koutani A, Iben Attya Andaloussi A. Penile gangrene and necrosis leading to death secondary to strangulation by condom catheter. Case Rep Urol. 2018;2018. doi: 10.1155/2018/3702412.
57. Zamarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. Am J Infect Control. 2008;36:476–480. doi: 10.1016/j.ajic.2007.11.007.
58. Gao Y, Danforth T, Ginsberg DA. Urologic management and complications in spinal cord injury patients: A 40- to 50-year follow-up study. Urology. 2017;104:52–58. doi: 10.1016/j.urology.2017.03.006.
59. Nicolle LE, Gupta K, Bradley SF et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. Published online ahead of print March 21, 2019.
60. Lamin E, Newman DK. Clean intermittent catheterization revisited. Int Urol Nephrol.

2016;48:931–939. doi: 10.1007/s11255-016-1236-9.

61. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–461. doi: 10.1016/s0022-5347(17)61055-3.
62. Elliot SP, Villar R, Duncan B. Bacteriuria management and urological evaluation of patients with spina bifida and neurogenic bladder: A multicenter survey. J Urol. 2005;173:217–220. doi: 10.1097/01.ju.0000146551.87110.f4.
63. Pidde TJ, Little JW. Hydronephrosis due to improper condom catheter use. J Am Paraplegia Soc. 1994;17:168–170. doi: 10.1080/01952307.1994.11735931.
64. Romo PGB, Smith CP, Cox A et al. Non-surgical urologic management of neurogenic bladder after spinal cord injury. World J Urol. 2018;36:1555–1568. doi: 10.1007/s00345-018-2419-z.
65. Vickrey BG, Shekelle P, Morton S, Clark K, Pathak M, Kamberg C. Prevention and management of urinary tract infections in paralyzed persons. Evid Rep Technol Assess (Summ) 1999:1–3.